Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Sees Significant Increase in Short Interest

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) was the recipient of a significant growth in short interest in July. As of July 31st, there was short interest totaling 2,273,103 shares, a growth of 56.9% from the July 15th total of 1,448,757 shares. Currently, 3.0% of the shares of the stock are short sold. Based on an average trading volume of 835,918 shares, the days-to-cover ratio is presently 2.7 days.

Nautilus Biotechnology Stock Down 1.3%

Shares of NAUT opened at $0.88 on Tuesday. The stock has a market capitalization of $112.04 million, a P/E ratio of -1.96 and a beta of 0.87. Nautilus Biotechnology has a twelve month low of $0.62 and a twelve month high of $4.31. The firm has a fifty day simple moving average of $1.65 and a two-hundred day simple moving average of $2.33.

Nautilus Biotechnology (NASDAQ:NAUT) last released its quarterly earnings data on Tuesday, July 28th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.03. The firm had revenue of $0.19 million during the quarter, compared to analysts’ expectations of $0.10 million.

Insider Buying and Selling at Nautilus Biotechnology

In other news, major shareholder Ah Equity Partners Bio Ii, L.L sold 5,000,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $2.35, for a total value of $11,750,000.00. Following the completion of the sale, the insider directly owned 971,885 shares in the company, valued at approximately $2,283,929.75. The trade was a 83.73% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 41.10% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of NAUT. Fayez Sarofim & Co bought a new position in Nautilus Biotechnology during the 2nd quarter valued at approximately $84,000. Corient Private Wealth LP bought a new stake in shares of Nautilus Biotechnology in the 2nd quarter worth approximately $308,000. Bank of America Corp DE purchased a new position in shares of Nautilus Biotechnology during the second quarter valued at approximately $144,000. Hsbc Holdings PLC purchased a new position in shares of Nautilus Biotechnology during the second quarter valued at approximately $91,000. Finally, Callan Family Office LLC bought a new position in shares of Nautilus Biotechnology during the second quarter valued at approximately $49,000. Hedge funds and other institutional investors own 50.71% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings cut shares of Nautilus Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, August 5th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $4.00.

About Nautilus Biotechnology

Nautilus Biotechnology is a life sciences company developing a next-generation proteomics platform that aims to provide high-resolution, single-molecule protein analysis. Its core technology combines proprietary microfluidics, advanced optics and custom reagents to capture and identify thousands of proteins simultaneously, offering researchers detailed insights into cellular processes and disease biology. The company’s platform is designed to improve sensitivity, reproducibility and throughput compared with traditional mass spectrometry approaches.

Founded in 2016 and headquartered in Seattle, Washington, Nautilus Biotechnology serves pharmaceutical and biotechnology companies, academic institutions and research organizations seeking to accelerate drug discovery and biomarker research.